General Information of Drug (ID: DMKP6BM)

Drug Name
2-Methylamino-succinic acid(NMDA) Drug Info
Synonyms
N-Methyl-D-aspartic acid; N-methyl-D-aspartic acid; NMDA; 6384-92-5; N-Methyl-D-aspartate; N-Methylaspartate; D-Aspartic acid, N-methyl-; N-Me-D-Asp-OH; (R)-2-(Methylamino)succinic acid; NMDA (N-Methyl-D-aspartic acid); Methyl aspartic acid; n-methyl-d-aspartic acid (nmda); UNII-1903B9Q6PI; N-Methyl aspartic acid; (2R)-2-(methylamino)butanedioic acid; 2-Methylamino-succinic acid; BRN 1724431; CHEMBL291278; CHEBI:31882; HOKKHZGPKSLGJE-GSVOUGTGSA-N; 1903B9Q6PI; N-Methyl-D-aspartic Acid, Hydrate; AK-44365; W-203368; N-Methyl-D-aspartic acid, 98%
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
22880
ChEBI ID
CHEMBL31882
CAS Number
CAS 6384-92-5
TTD Drug ID
DMKP6BM

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Glycine DMIOZ29 Allergic rhinitis CA08.0 Approved [10]
NBQX DMPHZI5 Neurological disorder 6B60 Phase 1 [11]
YM-90K DMWRT4L Convulsion 8A68.Z Discontinued in Phase 2 [12]
SPERMINE DMD4BFY N. A. N. A. Terminated [13]
L-689560 DMCVY4U Neurodegenerative disorder 8A20-8A23 Terminated [3]
L-698544 DMLRBN1 Alzheimer disease 8A20 Terminated [14]
DIZOCILPINE DMMGYXR Cerebrovascular ischaemia 8B1Z Terminated [15]
RPR-104632 DM9L50N N. A. N. A. Terminated [16]
L-698532 DMO9HM7 Neurological disorder 6B60 Terminated [17]
L-695902 DMT1DNS N. A. N. A. Terminated [14]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-689560 DMCVY4U Neurodegenerative disorder 8A20-8A23 Terminated [6]
D-aspartic acid DM7Z892 Discovery agent N.A. Investigative [6]
[3H]CPP DMR5UBF Discovery agent N.A. Investigative [6]
[3H]MDL105519 DMPKGHB Discovery agent N.A. Investigative [6]
[3H]CGP39653 DMITR7A Discovery agent N.A. Investigative [6]
homoquinolinic acid DMBW5DU Discovery agent N.A. Investigative [6]
[3H]dizocilpine DMEC2PF Discovery agent N.A. Investigative [6]
CGP61594 DM8KFZH Discovery agent N.A. Investigative [6]
(RS)-(tetrazol-5-yl)glycine DMYZCRF Discovery agent N.A. Investigative [6]
[3H]CGS19755 DM7H3JN Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cycloserine DMT1I52 Bacterial infection 1A00-1C4Z Approved [18]
D-Serine DM3YH4I N. A. N. A. Phase 4 [19]
ELIPRODIL DMIOGZM Multiple sclerosis 8A40 Phase 2 [20]
NBQX DMPHZI5 Neurological disorder 6B60 Phase 1 [11]
YM-90K DMWRT4L Convulsion 8A68.Z Discontinued in Phase 2 [12]
SPERMINE DMD4BFY N. A. N. A. Terminated [13]
L-689560 DMCVY4U Neurodegenerative disorder 8A20-8A23 Terminated [2]
L-698544 DMLRBN1 Alzheimer disease 8A20 Terminated [14]
DIZOCILPINE DMMGYXR Cerebrovascular ischaemia 8B1Z Terminated [15]
RPR-104632 DM9L50N N. A. N. A. Terminated [16]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-689560 DMCVY4U Neurodegenerative disorder 8A20-8A23 Terminated [5]
D-aspartic acid DM7Z892 Discovery agent N.A. Investigative [5]
[3H]CPP DMR5UBF Discovery agent N.A. Investigative [5]
[3H]MDL105519 DMPKGHB Discovery agent N.A. Investigative [5]
[3H]CGP39653 DMITR7A Discovery agent N.A. Investigative [5]
homoquinolinic acid DMBW5DU Discovery agent N.A. Investigative [5]
[3H]dizocilpine DMEC2PF Discovery agent N.A. Investigative [5]
CGP61594 DM8KFZH Discovery agent N.A. Investigative [5]
(RS)-(tetrazol-5-yl)glycine DMYZCRF Discovery agent N.A. Investigative [5]
[3H]CGS19755 DM7H3JN Discovery agent N.A. Investigative [5]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alpha 1-PI DMXC1K9 Alpha-1 antitrypsin deficiency 5C5A Approved [21]
ELIPRODIL DMIOGZM Multiple sclerosis 8A40 Phase 2 [20]
CP-101,606 DMIU19E Parkinson disease 8A00.0 Phase 2 [22]
CERC-301 DMSABRI Major depressive disorder 6A70.3 Phase 2 [23]
RGH-896 DMCHZAN Peripheral neuropathy 8C0Z Phase 2 [24]
MIJ821 DMN45RI Major depressive disorder 6A70.3 Phase 2 [25]
NBQX DMPHZI5 Neurological disorder 6B60 Phase 1 [11]
Neu-2000 DMNJTLC Cardiac arrest MC82 Phase 1 [26]
EVT100 DMAKWQD Major depressive disorder 6A70.3 Phase 1 [27]
YM-90K DMWRT4L Convulsion 8A68.Z Discontinued in Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [28]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [29]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [30]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [31]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [32]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [33]
Secobarbital DM14RF5 Epilepsy 8A60-8A68 Approved [34]
Gefitinib DM15F0X Colon adenocarcinoma Approved [35]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [36]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [37]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ethanol DMDRQZU Chronic pain MG30 Approved [38]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [29]
Carvedilol DMHTEAO Chronic heart failure BD1Z Approved [39]
Paclitaxel DMLB81S Breast carcinoma Approved [40]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [41]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [28]
Urokinase DM0GOUD Myocardial infarction BA41-BA43 Approved [42]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [43]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [31]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [32]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [44]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [45]
Methotrexate DM2TEOL Anterior urethra cancer Approved [46]
Quercetin DM3NC4M Obesity 5B81 Approved [47]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [48]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [49]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [50]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [51]
Ethanol DMDRQZU Chronic pain MG30 Approved [52]
Hydrocortisone DMGEMB7 Acne vulgaris ED80 Approved [53]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [54]
Selenium DM25CGV N. A. N. A. Approved [55]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [8]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [8]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [56]
Gabapentin DM6T924 Complex partial seizure 8A68.0 Approved [8]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [49]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [57]
Melphalan DMOLNHF Hematologic disease 3C0Z Approved [58]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [59]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glutamate receptor ionotropic NMDA 1 (NMDAR1) TTLD29N NMDZ1_HUMAN Inhibitor [2]
Glutamate receptor ionotropic NMDA 2A (NMDAR2A) TTKJEMQ NMDE1_HUMAN Inhibitor [3]
Glutamate receptor ionotropic NMDA 2B (NMDAR2B) TTN9D8E NMDE2_HUMAN Inhibitor [4]
Glutamate receptor ionotropic NMDA 2C (GluN2C) TT1M8OW NMDE3_HUMAN Agonist [5]
Glutamate receptor ionotropic NMDA 2D (GluN2D) TT5POTG NMDE4_HUMAN Agonist [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Post-Translational Modifications [7]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Post-Translational Modifications [7]
SH3 and multiple ankyrin repeat domains protein 2 (SHANK2) OTSQTPFQ SHAN2_HUMAN Gene/Protein Processing [8]
Tight junction protein ZO-1 (TJP1) OTBDCUPK ZO1_HUMAN Gene/Protein Processing [9]

References

1 2,4-Dihydro-3H-1,2,4-triazol-3-ones as anticonvulsant agents. J Med Chem. 1990 Oct;33(10):2772-7.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458).
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459).
7 Kukoamine B, an amide alkaloid, protects against NMDA-induced neurotoxicity and potential mechanisms in vitro. Neurochem Int. 2015 Aug;87:66-76. doi: 10.1016/j.neuint.2015.06.001. Epub 2015 Jun 9.
8 Establishment of a 13 genes-based molecular prediction score model to discriminate the neurotoxic potential of food relevant-chemicals. Toxicol Lett. 2022 Feb 1;355:1-18. doi: 10.1016/j.toxlet.2021.10.013. Epub 2021 Nov 5.
9 N-methyl-D-aspartic acid increases tight junction protein destruction in brain endothelial cell via caveolin-1-associated ERK1/2 signaling. Toxicology. 2022 Mar 30;470:153139. doi: 10.1016/j.tox.2022.153139. Epub 2022 Mar 4.
10 Glycine transport inhibitors for the treatment of schizophrenia: Symptom and disease modification. Curr Opin Drug Discov Devel. 2009 Jul;12(4):468-78.
11 Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65.
12 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
13 Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
14 Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
15 Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists. J Med Chem. 1995 Jun 23;38(13):2483-9.
16 Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
17 Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
18 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
19 Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
20 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
21 NMDA receptor stimulation induces reversible fission of the neuronal endoplasmic reticulum. PLoS One. 2009;4(4):e5250.
22 NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol. 2001 Oct 19;429(1-3):71-8.
23 Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice. Eur J Pharmacol. 2015 Nov 5;766:1-8.
24 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
25 Clinical pipeline report, company report or official report of Cadent Therapeutics.
26 Neu2000, an NR2B-selective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke. Drug News Perspect. 2010 Nov;23(9):549-56.
27 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
28 Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
29 Progesterone increases csk homologous kinase in HMC-1560 human mast cells and reduces cell proliferation. J Cell Biochem. 2007 Dec 1;102(5):1271-80. doi: 10.1002/jcb.21357.
30 Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
31 Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
32 Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer. 2006 Mar 15;118(6):1370-80. doi: 10.1002/ijc.21537.
33 Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
34 Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19.
35 Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
36 Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
37 SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
38 Downregulation of mitogen-activated protein kinases (MAPKs) in chronic ethanol-induced fatty liver. Toxicol Mech Methods. 2020 Jul;30(6):407-416. doi: 10.1080/15376516.2020.1747126. Epub 2020 Apr 1.
39 A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16657-62. doi: 10.1073/pnas.0707936104. Epub 2007 Oct 9.
40 The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
41 Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem. 2005 Sep 9;280(36):31498-507. doi: 10.1074/jbc.M505537200. Epub 2005 Jul 13.
42 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
43 Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
44 Cannabidiol induces osteoblast differentiation via angiopoietin1 and p38 MAPK. Environ Toxicol. 2020 Dec;35(12):1318-1325. doi: 10.1002/tox.22996. Epub 2020 Jul 13.
45 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
46 Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
47 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
48 THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
49 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
50 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
51 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
52 Ethanol impairs intestinal barrier function in humans through mitogen activated protein kinase signaling: a combined in vivo and in vitro approach. PLoS One. 2014 Sep 16;9(9):e107421. doi: 10.1371/journal.pone.0107421. eCollection 2014.
53 Hydrocortisone enhances the barrier properties of HBMEC/ci, a brain microvascular endothelial cell line, through mesenchymal-to-endothelial transition-like effects. Fluids Barriers CNS. 2015 Mar 5;12:7. doi: 10.1186/s12987-015-0003-0. eCollection 2015.
54 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
55 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
56 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
57 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
58 Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
59 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.